Calidi Biotherapeutics Granted US Patent for Proprietary Therapeutic Delivery Platform, Strengthening Company’s Intellectual Property Position in Immunotherapy

Calidi Biotherapeutics, Inc. has been granted a new patent by the US Patent and Trademark Office related to its proprietary SuperNova (SNV) technology platform. The SNV platform is composed of allogeneic, adipose-derived MSCs loaded with an oncolytic agent.